Study Evaluating Inhibitor Specificity in Hemophilia A
Phase 4
Withdrawn
- Conditions
- Hemophilia A
- Registration Number
- NCT00151385
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs (\> 50 ED) with hemophilia A who have developed inhibitors in response to treatment with any FVIII product(s). A group of patients with hemophilia A, who have no evidence of current or prior FVIII inhibitor will be included for comparison. The objective of this study is to describe the patterns of antibodies and associated epitopes in the study population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
· Patients with moderate or severe congenital hemophilia A, a current FVIII inhibitor, who have taken at least two different FVIII products during their lifetime.
Exclusion Criteria
- Patients who have had an inhibitor prior to their current inhibitor.
- Patients with immune disorders.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Description of the patterns of antibodies and associated epitopes in a subset of previously treated patients with hemophilia A.
- Secondary Outcome Measures
Name Time Method